Marc Lopez, Emerence Crompot, Emmanuelle Josselin, Anne Farina, Marion Rubis, Remy Castellano, Joanna Fares, Maria Wehbe, Yves Collette, Emmanuelle Charafe, Stéphanie Blanchin, François Romagne, Anikó Pálfi, Torsten Hechler, Andreas Pahl, Hatem A Azim, Florence Lhospice, Emilie Mamessier, François Bertucci, Jack Elands, Xavier Préville, Daniel Olive
{"title":"ETx-22：一种新型的连接蛋白-4导向抗体药物共轭物，在低连接蛋白-4表达的肿瘤中显示出安全性和强大的抗肿瘤活性。","authors":"Marc Lopez, Emerence Crompot, Emmanuelle Josselin, Anne Farina, Marion Rubis, Remy Castellano, Joanna Fares, Maria Wehbe, Yves Collette, Emmanuelle Charafe, Stéphanie Blanchin, François Romagne, Anikó Pálfi, Torsten Hechler, Andreas Pahl, Hatem A Azim, Florence Lhospice, Emilie Mamessier, François Bertucci, Jack Elands, Xavier Préville, Daniel Olive","doi":"10.1158/2767-9764.CRC-24-0176","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>ETx-22, a novel ADC combining a tumor nectin-4-specific antibody and an innovative linker to exatecan, demonstrates significant and durable responses in low-target-expressing tumor models that are resistant to MMAE-based EV and has a better toxicity profile. This new ADC has the potential to benefit additional patient populations beyond its current indication.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"2998-3012"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583010/pdf/","citationCount":"0","resultStr":"{\"title\":\"ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.\",\"authors\":\"Marc Lopez, Emerence Crompot, Emmanuelle Josselin, Anne Farina, Marion Rubis, Remy Castellano, Joanna Fares, Maria Wehbe, Yves Collette, Emmanuelle Charafe, Stéphanie Blanchin, François Romagne, Anikó Pálfi, Torsten Hechler, Andreas Pahl, Hatem A Azim, Florence Lhospice, Emilie Mamessier, François Bertucci, Jack Elands, Xavier Préville, Daniel Olive\",\"doi\":\"10.1158/2767-9764.CRC-24-0176\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Significance: </strong>ETx-22, a novel ADC combining a tumor nectin-4-specific antibody and an innovative linker to exatecan, demonstrates significant and durable responses in low-target-expressing tumor models that are resistant to MMAE-based EV and has a better toxicity profile. This new ADC has the potential to benefit additional patient populations beyond its current indication.</p>\",\"PeriodicalId\":72516,\"journal\":{\"name\":\"Cancer research communications\",\"volume\":\" \",\"pages\":\"2998-3012\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583010/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2767-9764.CRC-24-0176\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0176","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.
Significance: ETx-22, a novel ADC combining a tumor nectin-4-specific antibody and an innovative linker to exatecan, demonstrates significant and durable responses in low-target-expressing tumor models that are resistant to MMAE-based EV and has a better toxicity profile. This new ADC has the potential to benefit additional patient populations beyond its current indication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
